Pancreatic Cancer Research

ResearcherPhilipps University of MarburgNo recent work listed

Tashinga E. Bapiro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1483-2161; OpenAlex author ID A5041621307. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper

Papers 9

  1. T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Canc… Co-author DOI 10.1158/1535-7163.mct-20-0620↗
  2. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1398↗
  3. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. Co-author DOI 10.1002/path.4727↗
  4. Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. Co-author DOI 10.1038/bjc.2014.288↗
  5. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2012-302529↗
  6. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0067330↗
  7. Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. Co-author DOI 10.1038/bjc.2012.450↗
  8. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. Co-author DOI 10.1084/jem.20111923↗
  9. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Co-author DOI 10.1158/2159-8290.cd-11-0242↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Duncan Ian Jodrell · 8 shared papers, 2012–2021 · strength 0.37
  2. Frances M. Richards · 5 shared papers, 2012–2021 · strength 0.26
  3. David Arthur Tuveson · 6 shared papers, 2012–2019 · strength 0.24
  4. Kristopher K. Frese · 5 shared papers, 2012–2019 · strength 0.20
  5. Natalie Cook · 5 shared papers, 2012–2014 · strength 0.17
  6. Albrecht Neeße · 4 shared papers, 2012–2014 · strength 0.14
  7. Dandan Li · 1 shared paper, 2021 · strength 0.10
  8. Yaroslav Teper · 1 shared paper, 2021 · strength 0.10
  9. Rebecca A. Sorber · 1 shared paper, 2021 · strength 0.10
  10. Udo Rudloff · 1 shared paper, 2021 · strength 0.10
  11. Christine Feig · 2 shared papers, 2013–2016 · strength 0.08
  12. Aurélie Courtin · 2 shared papers, 2013–2014 · strength 0.08
  13. Lindsey A. Baker · 1 shared paper, 2019 · strength 0.07
  14. Mariano Ponz‐Sarvisé · 1 shared paper, 2019 · strength 0.07
  15. Iok In Christine Chio · 1 shared paper, 2019 · strength 0.07
  16. Vincenzo Corbo · 1 shared paper, 2019 · strength 0.07
  17. Tobiloba E. Oni · 1 shared paper, 2019 · strength 0.07
  18. Chang‐Il Hwang · 1 shared paper, 2019 · strength 0.07
  19. Dannielle D. Engle · 1 shared paper, 2019 · strength 0.07
  20. Youngkyu Park · 1 shared paper, 2019 · strength 0.07
  21. Kenneth H. Yu · 1 shared paper, 2019 · strength 0.07
  22. Hervé Tiriac · 1 shared paper, 2019 · strength 0.07
  23. Daniel Öhlund · 1 shared paper, 2019 · strength 0.07
  24. Michael A. Jacobetz · 2 shared papers, 2012–2013 · strength 0.06
  25. Elisabete Carapuça · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.